Effectiveness of Long-Term Treatment with Brodalumab on Anxiety or Depressive Symptoms in Japanese Patients with Psoriasis: The ProLOGUE Study

[1]  M. Komine,et al.  English version of Japanese guidance for use of biologics for psoriasis (the 2022 version) , 2022, The Journal of dermatology.

[2]  K. Murotani,et al.  Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: The ProLOGUE study. , 2022, Journal of dermatological science.

[3]  K. Murotani,et al.  Difference in health‐related quality of life between anxiety and depressive symptoms in Japanese patients with plaque psoriasis: the ProLOGUE study , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  R. S. Bakar,et al.  Depression and anxiety among patients with psoriasis: A correlation with quality of life and associated factors. , 2021, Journal of Taibah University Medical Sciences.

[5]  M. Sebastian,et al.  Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  T. Nomura,et al.  Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study. , 2021, Journal of dermatological science.

[7]  A. Costanzo,et al.  Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study , 2020, Acta dermato-venereologica.

[8]  M. Lebwohl,et al.  The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities. , 2020, The Journal of clinical and aesthetic dermatology.

[9]  H. Miot,et al.  Prevalence and factors associated with depression and anxiety in patients with psoriasis. , 2020, Journal of clinical nursing.

[10]  E. H. Thompson,et al.  Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis , 2020, JAMA dermatology.

[11]  M. J. Hashim,et al.  Global burden of psoriasis – comparison of regional and global epidemiology, 1990 to 2017 , 2020, International journal of dermatology.

[12]  T. Shibata,et al.  Regulatory changes after the enforcement of the new Clinical Trials Act in Japan , 2020, Japanese Journal of Clinical Oncology.

[13]  L. Puig,et al.  The safety of brodalumab for the treatment of psoriasis , 2020, Expert opinion on drug safety.

[14]  H. Nakagawa,et al.  Japanese guidance for use of biologics for psoriasis (the 2019 version) , 2020, The Journal of dermatology.

[15]  A. Downs,et al.  The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study , 2020, The Journal of dermatological treatment.

[16]  F. Tubach,et al.  Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  J. Koo,et al.  Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review. , 2019, Cutis.

[18]  J. Martínez-Ortega,et al.  Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study. , 2019, Journal of psychosomatic research.

[19]  A. Yang,et al.  Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept. , 2019, Annales de dermatologie et de venereologie.

[20]  A. Bulbena,et al.  Patients with Moderate to Severe Psoriasis Associate with Higher Risk of Depression and Anxiety Symptoms: Results of a Multivariate Study of 300 Spanish Individuals with Psoriasis. , 2019, Acta dermato-venereologica.

[21]  A. Armstrong,et al.  Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: a population-based study , 2018, The Journal of dermatological treatment.

[22]  S. González‐Parra,et al.  Psoriasis and Depression: The Role of Inflammation. , 2019, Actas dermo-sifiliograficas.

[23]  K. Reich,et al.  Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  A. Miyake,et al.  Evidence for Transdiagnostic Repetitive Negative Thinking and Its Association with Rumination, Worry, and Depression and Anxiety Symptoms: A Commonality Analysis. , 2017, Collabra. Psychology.

[25]  B. Strober,et al.  Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR) , 2018, Journal of the American Academy of Dermatology.

[26]  A. Armstrong,et al.  Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[27]  W. Gulliver,et al.  The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[28]  S. Feldman,et al.  Psoriasis, Depression, and Inflammatory Overlap: A Review , 2017, American Journal of Clinical Dermatology.

[29]  Hanna Przybyła-Basista,et al.  Toward a better understanding of social anxiety and depression in psoriasis patients: The role of determinants, mediators, and moderators. , 2017, Journal of psychosomatic research.

[30]  S. Feldman,et al.  Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[31]  A. Gottlieb,et al.  A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis , 2016, The British journal of dermatology.

[32]  Takashi Fukuda,et al.  Developing a Japanese version of the EQ-5D-5L value set , 2015 .

[33]  L. Arends,et al.  The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. , 2014, The Journal of investigative dermatology.

[34]  H. Nakagawa,et al.  Japanese guidance for use of biologics for psoriasis (the 2013 version) , 2013, The Journal of dermatology.

[35]  A. Zbrozek,et al.  The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument , 1993, PharmacoEconomics.

[36]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[37]  T. Strine,et al.  The PHQ-8 as a measure of current depression in the general population. , 2009, Journal of affective disorders.

[38]  B. Löwe,et al.  A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.

[39]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[40]  R. Spitzer,et al.  The PHQ-9: A new depression diagnostic and severity measure , 2002 .

[41]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.